Yamamoto S - Search Results

1

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H. Hayashi T, et al. Among authors: yamamoto n, yamamoto s. Int J Clin Oncol. 2024 Nov;29(11):1616-1631. doi: 10.1007/s10147-024-02623-y. Epub 2024 Sep 11. Int J Clin Oncol. 2024. PMID: 39259324

2

Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer.

Boku N, Yamamoto S. Boku N, et al. Among authors: yamamoto s. Clin Colorectal Cancer. 2018 Dec;17(4):251-254. doi: 10.1016/j.clcc.2018.07.012. Epub 2018 Aug 1. Clin Colorectal Cancer. 2018. PMID: 30149985

3

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer.

Takamizawa S, Shoji H, Hirano H, Izutsu K, Yamamoto S, Iwasa S, Honma Y, Okita N, Takashima A, Kato K, Boku N. Takamizawa S, et al. Among authors: yamamoto s. Case Rep Oncol. 2021 Feb 25;14(1):85-89. doi: 10.1159/000512821. eCollection 2021 Jan-Apr. Case Rep Oncol. 2021. PMID: 33776687 Free PMC article.

4

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.

Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Yamamoto S, et al. Among authors: yamamoto y. BMC Cancer. 2021 Oct 29;21(1):1159. doi: 10.1186/s12885-021-08890-6. BMC Cancer. 2021. PMID: 34715820 Free PMC article.

5

The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan.

Yamamoto S, Sakakibara N, Hirano H, Morizane C, Honma Y, Hijioka S, Okusaka T, Higashi T, Kawai A. Yamamoto S, et al. Sci Rep. 2022 Oct 20;12(1):17601. doi: 10.1038/s41598-022-22718-8. Sci Rep. 2022. PMID: 36266484 Free PMC article.

6

Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan.

Yamamoto S, Sakakibara N, Hirano H, Morizane C, Honma Y, Hijioka S, Okusaka T, Higashi T, Kawai A. Yamamoto S, et al. Sci Rep. 2022 Dec 19;12(1):21917. doi: 10.1038/s41598-022-26509-z. Sci Rep. 2022. PMID: 36536045 Free PMC article. No abstract available.

7

Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab.

Kadono T, Iwasa S, Nagashima K, Oshima K, Yamamoto S, Hirano H, Okita N, Shoji H, Honma Y, Takashima A, Kato K, Ushijima T, Boku N. Kadono T, et al. Among authors: yamamoto s. Cancer Med. 2023 Apr;12(8):9322-9331. doi: 10.1002/cam4.5689. Epub 2023 Feb 15. Cancer Med. 2023. PMID: 36789624 Free PMC article.

8

Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.

Cho H, Abe S, Nonaka S, Suzuki H, Yoshinaga S, Okuma K, Yamamoto S, Daiko H, Kato K, Sekine S, Boku N, Saito Y. Cho H, et al. Among authors: yamamoto s. Dis Esophagus. 2024 Apr 27;37(5):doae004. doi: 10.1093/dote/doae004. Dis Esophagus. 2024. PMID: 38266034

9

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Masuda K, et al. Among authors: yamamoto s. BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y. BMC Cancer. 2019. PMID: 31638948 Free PMC article.

10

Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer.

Kawai S, Fukuda N, Yamamoto S, Mitani S, Omae K, Wakatsuki T, Kato K, Kadowaki S, Takahari D, Boku N, Muro K, Machida N. Kawai S, et al. Among authors: yamamoto s. BMC Cancer. 2020 Apr 21;20(1):338. doi: 10.1186/s12885-020-06865-7. BMC Cancer. 2020. PMID: 32316940 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,628 results

Search Page

Filters